BiotechTube

R744

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hemodialysis Patients

Conditions

Hemodialysis Patients

Trial Timeline

Feb 1, 2007 → Oct 1, 2008

NCT ID
NCT00433693

About R744

R744 is a phase 3 stage product being developed by Chugai Pharmaceutical for Hemodialysis Patients. The current trial status is completed. This product is registered under clinical trial identifier NCT00433693. Target conditions include Hemodialysis Patients.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT00433693Phase 3Completed

Competing Products

20 competing products in Hemodialysis Patients

See all competitors
ProductCompanyStageHype Score
R744 + R744 + rHuEPO + rHuEPO + R744 placebo + rHuEPO placeboChugai PharmaceuticalPhase 3
77
R744 + R744Chugai PharmaceuticalPhase 3
77
roxadustatAstellas PharmaPhase 3
77
ASP7991Astellas PharmaPhase 1
33
roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
77
roxadustatAstellas PharmaPhase 3
77
ASP1585Astellas PharmaPhase 2
52
Kiklin capsulesAstellas PharmaPre-clinical
23
DoravirineMerckApproved
85
BPS804 + PlaceboNovartisPhase 2
52
PA21 + Sevelamer hydrochlorideKissei PharmaceuticalPhase 3
76
PA21 + PA21 + PA21 + PA21 + PlaceboKissei PharmaceuticalPhase 2
51
PA21Kissei PharmaceuticalPhase 3
76
PA21Kissei PharmaceuticalPhase 3
76
[¹⁴C]EtelcalcetideAmgenPhase 1
32
Epoetin HospiraPfizerPhase 3
76
Epoetin HospiraPfizerPhase 3
76
sodium thiosulfateSanofiPre-clinical
22
EnoxaparineSanofiApproved
84
Alirocumab 150 MG/ML [Praluent]Regeneron PharmaceuticalsPhase 3
76

Other Products from Chugai Pharmaceutical

Satralizumab 120 mgApproved
85
Pegasys® + Pegasys®Approved
85
ED-71 + Alfacalcidol + ED-71 placebo + Alfacalcidol placeboPhase 3
77
R744 + Epoetin betaPhase 3
77
EmicizumabPhase 3
77